Literature DB >> 1879091

Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype.

F Halle1, A M Prieur.   

Abstract

Methotrexate therapy was evaluated in 30 children with juvenile chronic arthritis according to the type of onset. The systemic form seemed less responsive than the ANA positive form with a polyarticular course or polyarticular onset. The clinical improvement, particularly in the ANA positive polyarticular course was confirmed by a significant decrease in the values of the ESR. Side effects occurred in 12 patients and consisted of gastrointestinal upset, mouth ulcers, slight leucopenia and elevated transaminases. They led to discontinuation of the treatment in only one child. Concomitant therapy could be stopped in 50% of the patients with an ANA positive polyarticular course, but remained necessary in the two other groups. These results indicate a differential effect of MTX therapy according to the type of JCA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879091

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

Review 1.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis.

Authors:  W al-Sewairy; A al-Mazyed; S al-Balaa; S Bahabri
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Juvenile idiopathic arthritis: management and therapeutic options.

Authors:  Natasha M Ruth; Murray H Passo
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 4.  Juvenile rheumatoid arthritis: therapeutic perspectives.

Authors:  Ian C Chikanza
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens.

Authors:  Mara L Becker; Carlos D Rosé; Randy Q Cron; David D Sherry; Warren B Bilker; Ebbing Lautenbach
Journal:  J Rheumatol       Date:  2010-03-01       Impact factor: 4.666

6.  Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis.

Authors:  A Ravelli; S Viola; B Ramenghi; G Di Fuccia; N Ruperto; L Zonta; A Martini
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

7.  Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Hum Genomics Proteomics       Date:  2010-06-22

Review 8.  Systemic JIA: new developments in the understanding of the pathophysiology and therapy.

Authors:  Sebastiaan J Vastert; Wietse Kuis; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

Review 9.  Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

Authors:  E H Giannini; J T Cassidy
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 10.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.